Stem cell transplant with added T-cells for blood cancers
Part of Blood & lymphatic clinical trials.
This Phase 1 study tests a stem cell transplant plan that uses donor T-cells that have been specially processed and then added back. It aims to see if this approach is safer and works better for children and adults with serious blood cancers who need a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your age is over 1 month and under 45 years, and you weigh at least 10 kg (about 22 lb).
- You must be eligible for a stem cell transplant under the related study, NCT 04249830.
- You have a life-threatening blood cancer where a transplant is recommended (such as high-risk ALL or AML, myelodysplastic syndrome, JMML, or certain lymphomas).
- Before the added-cell step, you already had an αβ-depleted stem cell transplant and your new blood-forming cells are working (myeloid engraftment).
- You must not currently have moderate-to-severe graft-versus-host disease (GVHD) that needs high-dose steroids.
- You (and the donor, if applicable) must be able and willing to do an extra blood-cell collection before the study cells are made, and you cannot be pregnant around the time of collection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a special donor stem cell transplant where the donor’s immune cells are reduced, aiming to lower harmful immune attacks after transplant. It may help children and young adults with certain high-risk blood cancers or rare bone marrow disorders.
This Phase 1 trial studies a type of stem cell transplant that removes certain immune cells (called T-cells) to help treat serious blood and immune diseases in children and young adults. It’s meant for patients who need a transplant but may not have an identical donor available in time.
This study tests a special stem cell transplant for children and young adults with certain high-risk blood cancers or bone marrow diseases. It uses a half-matched family donor and a technique to remove specific cells, which may lower the risk of side effects and help the body accept the new cells.
This trial tests a new way to perform a stem cell transplant for people with high-risk blood cancers who don't have a fully matched donor. It aims to offer a treatment option when a standard donor isn't available.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This trial tests a type of stem cell transplant that removes certain immune cells (alpha-beta T cells and CD19 B cells) from the donor cells. This may help prevent graft-versus-host disease and other complications in patients with blood cancers who do not have a matched sibling donor.
Hear when a new Hematologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.